Ignyta and EORTC Announce Entrectinib Selected as First Investigational Cancer Agent to be Included in EORTC SPECTA Precision Medicine Clinical Trial Program
November 30, 2015 at 07:00 AM EST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, and the European Organisation for Research and Treatment of ...